Nurix Therapeutics, Inc. (NRIX)
Develops experimental drugs that destroy cancer-causing proteins to treat blood cancers and autoimmune diseases.
$23.73+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+114.9%
The outlook
NRIX is trading near the top of its 52-week range, well above both its 50- and 200-day moving averages. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and their average price target sits roughly 40% above the current price. The data reflects strong technical and sentiment positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 16 analysts
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Price targetAvg target +40% vs current price
Analyst price target
~12-month · 16 analysts$33.13average target+39.6% vs now
Now $23.73
Low $25.00High $45.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.46B
52-wk high
$25.09
52-wk low
$8.20
50-day avg
$19.75
200-day avg
$16.82
Trailing P/E
—